The global antibiotic scenario has deteriorated considerably due to rising resistance in existing medication, lack of new medicines and increasingly resistant and newer organisms. The equation became more complicated when most of pharma majors distanced themselves from the anti-infective development and moved towards the chronic illness space.
Against this backdrop, Wockhardt Discovery engaged itself in the pursuit of developing antibiotics with the vision of targeting the realm of unmet medical need. 20 years of thorough research by discovery team yielded in 5 major drugs.
These drugs have shown promising results in the treatment of many serious bacterial infections, some with no currently available treatment for infections in respiratory, urinary tract, blood and abdominal regions.
These products, currently in various phases of clinical research, have already received the coveted Qualified Infectious Disease Product (QIDP) status from US FDA. This QIDP receipt is a critical success for Wockhardt as it becomes the entity with the highest number of QIDP approvals globally.
Wockhardt Bio AG is a subsidiary of Wockhardt Limited, headquartered in Mumbai, India. Wockhardt Bio AG is active in the development, manufacturing, and marketing of Pharmaceutical and Bio-pharmaceutical formulations, and caters primarily to markets in the United States, the United Kingdom, Ireland, France, and Latine Americas.
Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.